Year: 2026
Type: review
Abstract: The epidermal growth factor receptor (EGFR/ErbB1) is a critical regulator of cellular proliferation and differentiation. While its role in oncology is well-characterized, its contribution to glucose homeostasis has emerged as a significant area of metabolic research. This mini-review synthesizes current evidence regarding the seven EGFR ligands—EGF, TGFα, amphiregulin, HB-EGF, betacellulin, epiregulin, and epigen—in regulating beta cell mass, insulin secretion, hepatic gluconeogenesis, and peripheral insulin sensitivity. We critically evaluate the transition from mechanistic in vitro studies to preclinical rodent models, while acknowledging the current lack of human clinical validation. Furthermore, we discuss the metabolic paradox of EGFR tyrosine kinase inhibitors (TKIs) and the safety considerations regarding the mitogenic potential of these ligands. By highlighting emerging evidence and structural innovations such as chimeric ligands, this review provides a roadmap for future translational research in the EGFR/ErbB metabolic signaling axis.
Source: Frontiers in Endocrinology
Institutions: Hong Kong Polytechnic University, Inner Mongolia University
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7162766949